89 related articles for article (PubMed ID: 28085002)
1. HCV intergenotype 2k/1b recombinant detected in a DAA-treated patient in Italy.
Paolucci S; Premoli M; Ludovisi S; Mondelli MU; Baldanti F
Antivir Ther; 2017; 22(4):365-368. PubMed ID: 28085002
[TBL] [Abstract][Full Text] [Related]
2. Origin, prevalence and response to therapy of hepatitis C virus genotype 2k/1b chimeras.
Susser S; Dietz J; Schlevogt B; Zuckerman E; Barak M; Piazzolla V; Howe A; Hinrichsen H; Passmann S; Daniel R; Cornberg M; Mangia A; Zeuzem S; Sarrazin C
J Hepatol; 2017 Oct; 67(4):680-686. PubMed ID: 28619439
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness and safety of sofosbuvir plus ribavirin for HCV genotype 2 patients 65 and over with or without cirrhosis.
Ogawa E; Furusyo N; Nomura H; Takahashi K; Higashi N; Kawano A; Dohmen K; Satoh T; Azuma K; Nakamuta M; Koyanagi T; Kato M; Shimoda S; Kajiwara E; Hayashi J;
Antiviral Res; 2016 Dec; 136():37-44. PubMed ID: 27789224
[TBL] [Abstract][Full Text] [Related]
4. Rate and predictors of treatment failure to all-oral HCV regimens outside clinical trials.
Arias A; Aguilera A; Soriano V; Benítez-Gutiérrez L; Lledó G; Navarro D; Treviño A; Otero E; Peña JM; Cuervas-Mons V; de Mendoza C
Antivir Ther; 2017; 22(4):307-312. PubMed ID: 27341294
[TBL] [Abstract][Full Text] [Related]
5. Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease.
Charlton M; Everson GT; Flamm SL; Kumar P; Landis C; Brown RS; Fried MW; Terrault NA; O'Leary JG; Vargas HE; Kuo A; Schiff E; Sulkowski MS; Gilroy R; Watt KD; Brown K; Kwo P; Pungpapong S; Korenblat KM; Muir AJ; Teperman L; Fontana RJ; Denning J; Arterburn S; Dvory-Sobol H; Brandt-Sarif T; Pang PS; McHutchison JG; Reddy KR; Afdhal N;
Gastroenterology; 2015 Sep; 149(3):649-59. PubMed ID: 25985734
[TBL] [Abstract][Full Text] [Related]
6. Sofosbuvir-based salvage therapy for HCV infection in cirrhotic patients with DAA failure and multidrug resistance.
Abdurakhmanov DT; Rozina TP; Nikulkina EN; Nabatchikova EA; Chulanov VP; Moiseev SV
Antivir Ther; 2018; 23(8):705-708. PubMed ID: 30265242
[TBL] [Abstract][Full Text] [Related]
7. Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial.
Manns M; Samuel D; Gane EJ; Mutimer D; McCaughan G; Buti M; Prieto M; Calleja JL; Peck-Radosavljevic M; Müllhaupt B; Agarwal K; Angus P; Yoshida EM; Colombo M; Rizzetto M; Dvory-Sobol H; Denning J; Arterburn S; Pang PS; Brainard D; McHutchison JG; Dufour JF; Van Vlierberghe H; van Hoek B; Forns X;
Lancet Infect Dis; 2016 Jun; 16(6):685-697. PubMed ID: 26907736
[TBL] [Abstract][Full Text] [Related]
8. Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS).
Bourlière M; Bronowicki JP; de Ledinghen V; Hézode C; Zoulim F; Mathurin P; Tran A; Larrey DG; Ratziu V; Alric L; Hyland RH; Jiang D; Doehle B; Pang PS; Symonds WT; Subramanian GM; McHutchison JG; Marcellin P; Habersetzer F; Guyader D; Grangé JD; Loustaud-Ratti V; Serfaty L; Metivier S; Leroy V; Abergel A; Pol S
Lancet Infect Dis; 2015 Apr; 15(4):397-404. PubMed ID: 25773757
[TBL] [Abstract][Full Text] [Related]
9. Dual sofosbuvir and ribavirin therapy for chronic hepatitis C infection.
Tang L; Ward H; Kattakuzhy S; Wilson E; Kottilil S
Expert Rev Gastroenterol Hepatol; 2016; 10(1):21-36. PubMed ID: 26558305
[TBL] [Abstract][Full Text] [Related]
10. Week 4 response predicts sustained virological response to all-oral direct-acting antiviral-based therapy in cirrhotic patients with hepatitis C virus genotype 3 infection.
Pineda JA; Morano-Amado LE; Granados R; Macías J; Téllez F; García-Deltoro M; Ríos MJ; Collado A; Delgado-Fernández M; Suárez-Santamaría M; Serrano M; Miralles-Álvarez C; Neukam K; ;
Clin Microbiol Infect; 2017 Jun; 23(6):409.e5-409.e8. PubMed ID: 28137633
[TBL] [Abstract][Full Text] [Related]
11. Sofosbuvir-based therapy for patients with chronic hepatitis C: Early experience of its efficacy and safety in Korea.
Cho Y; Cho EJ; Lee JH; Yu SJ; Yoon JH; Kim YJ
Clin Mol Hepatol; 2015 Dec; 21(4):358-64. PubMed ID: 26770924
[TBL] [Abstract][Full Text] [Related]
12. Treatment failure with new hepatitis C drugs.
Soriano V; Vispo E; Poveda E; Labarga P; Barreiro P
Expert Opin Pharmacother; 2012 Feb; 13(3):313-23. PubMed ID: 22242928
[TBL] [Abstract][Full Text] [Related]
13. Impact of different sofosbuvir based treatment regimens on the biochemical profile of chronic hepatitis C genotype 4 patients.
Elsharkawy A; Eletreby R; Fouad R; Soliman Z; Abdallah M; Negm M; Mohey M; Esmat G
Expert Rev Gastroenterol Hepatol; 2017 Aug; 11(8):773-778. PubMed ID: 28480808
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of ledipasvir and sofosbuvir, with or without ribavirin, for 12 weeks in patients with HCV genotype 3 or 6 infection.
Gane EJ; Hyland RH; An D; Svarovskaia E; Pang PS; Brainard D; Stedman CA
Gastroenterology; 2015 Nov; 149(6):1454-1461.e1. PubMed ID: 26261007
[TBL] [Abstract][Full Text] [Related]
15. Prevention and management of treatment failure to new oral hepatitis C drugs.
Benítez-Gutiérrez L; Barreiro P; Labarga P; de Mendoza C; Fernandez-Montero JV; Arias A; Peña JM; Soriano V
Expert Opin Pharmacother; 2016 Jun; 17(9):1215-23. PubMed ID: 27149603
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness of telaprevir or boceprevir in treatment-experienced patients with HCV genotype 1 infection and cirrhosis.
Hézode C; Fontaine H; Dorival C; Zoulim F; Larrey D; Canva V; De Ledinghen V; Poynard T; Samuel D; Bourliere M; Alric L; Raabe JJ; Zarski JP; Marcellin P; Riachi G; Bernard PH; Loustaud-Ratti V; Chazouilleres O; Abergel A; Guyader D; Metivier S; Tran A; Di Martino V; Causse X; Dao T; Lucidarme D; Portal I; Cacoub P; Gournay J; Grando-Lemaire V; Hillon P; Attali P; Fontanges T; Rosa I; Petrov-Sanchez V; Barthe Y; Pawlotsky JM; Pol S; Carrat F; Bronowicki JP;
Gastroenterology; 2014 Jul; 147(1):132-142.e4. PubMed ID: 24704719
[TBL] [Abstract][Full Text] [Related]
17. Early HCV RNA changes in patients with chronic hepatitis C treated with peginterferon alfa 2b and ribavirin.
Gallegos-Orozco JF; Fuentes AP; Olivera-Martinez MA; Gutiérrez-Reyes G; Cortina D; Oregel JA; Pérez-Pruna C; Sixtos MS; Cruz-Castellanos S; Soto-Ramírez LE; Rodríguez-Díaz R; Fuentes-Romero L; Gutiérrez-Ruiz MC; Kershenobich D
Rev Invest Clin; 2003; 55(2):138-42. PubMed ID: 12827916
[TBL] [Abstract][Full Text] [Related]
18. Defining the possibilities: is short duration treatment of chronic hepatitis C genotype 1 with sofosbuvir-containing regimens likely to be as effective as current regimens?
Nafisi S; Roy S; Gish R; Manch R; Kohli A
Expert Rev Anti Infect Ther; 2016; 14(1):41-56. PubMed ID: 26654939
[TBL] [Abstract][Full Text] [Related]
19. Sofosbuvir plus simeprevir for the treatment of HCV genotype 4 patients with advanced fibrosis or compensated cirrhosis is highly efficacious in real life.
Willemse SB; Baak LC; Kuiken SD; van der Sluys Veer A; Lettinga KD; van der Meer JT; Depla AC; Tuynman H; van Nieuwkerk CM; Schinkel CJ; Kwa D; Reesink HW; van der Valk M
J Viral Hepat; 2016 Dec; 23(12):950-954. PubMed ID: 27405785
[TBL] [Abstract][Full Text] [Related]
20. Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation.
Charlton M; Gane E; Manns MP; Brown RS; Curry MP; Kwo PY; Fontana RJ; Gilroy R; Teperman L; Muir AJ; McHutchison JG; Symonds WT; Brainard D; Kirby B; Dvory-Sobol H; Denning J; Arterburn S; Samuel D; Forns X; Terrault NA
Gastroenterology; 2015 Jan; 148(1):108-17. PubMed ID: 25304641
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
